Check out the second part of last week's story on a novel Parkinson's disease peptide therapeutic over at Tides Global!
Last week, I shared a story about preclinical research into a peptide treatment for Parkinson's disease. In my follow-up, I look at the ongoing clinical studies being conducted with this drug candidate and discuss with leading Parkinson's experts about how it could change the game for patients: https://lnkd.in/eEaf7quJ
Delivering Innovation with Generative AI | Agentic workflows | Responsible AI | Author | 11 Patents | Chief Data Scientist | ex GE
#artificialintelligence has already started accelerating #drugdiscovery from years to months. AI-driven drug discovery identified TNIK as an anti-fibrotic target, leading to INS018_055, a promising small-molecule inhibitor with anti-fibrotic and anti-inflammatory properties. This work by Insilico Medicine completed in 18 months, showcases the potential of AI in rapidly advancing preclinical candidates for fibrotic diseases. Detailed study: https://lnkd.in/dzMDRUQ8 Insilico's AI-Generated Drug in Human Trials: https://lnkd.in/duKD-Wx3
#Heme Today reports in a preclinical mouse model pharmacologic iron restriction benefited pts with transfusion-independent #myelodysplasticsyndromes, #luspatercept enhancing these benefits: #vamifeport, #ferroportin, #FPNC326S, #MDS https://lnkd.in/e_KE-aS6
From a preclinical mouse model reported on #Heme Today --- Iron restriction, not excess, brings benefit in transfusion-independent #myelodysplasticsyndromes. These favorable effects are enhanced by #luspatercept: #vamifeport, #ferroportin, #FPNC326S, #MDS https://lnkd.in/e_KE-aS6
InMed's INM-901 is a novel, small molecule drug candidate in development for the treatment of #Alzheimer's disease. Preclinical studies of INM-901 demonstrate neuroprotective effects, reduced #neuroinflammation, an ability to promote the growth of neurites and improvement in behavior, cognitive function and memory. INM-901 may target several biological pathways associated with #AlzheimersDisease with studies indicating it targets CB1, CB2 and PPAR pathways. CEO Eric A. Adams presents InMed's INM-901 program in this video: https://ow.ly/41Ab50SWjN9 $INM
Argenica Therapeutics is developing a novel peptide drug, ARG-007, that has shown great results in preclinical models of ischaemic stroke and is now being tested in a Phase 2 trial in ischaemic stroke patients in hospitals across Australia. The way the drug was discovered and the mechanism by which it works to reduce brain injury gives a solid scientific basis for progressing this drug through clinical trials. Joining us to talk more about the discovery of ARG-007 and it’s unique mechanism of action is Argenica’s Chief Scientific Officer, and inventor of ARG-007, Prof Bruno Meloni. Joining Bruno is Argenica’s CEO Dr Liz Dallimore Spotify: https://spoti.fi/3NrDvCd Stewart Walters Holly Walters Riley Maring Dianne Angus Liddy McCall Meghan Thomas Emma Waldon Adam Edwards MarketOpen #ArgenicaTherapeutics #AGN #ARG007 #BrainInjury #Stroke #Science #ClinicalTrials
[Blog] There remains a significant need to develop new therapeutic solutions for pulmonary fibrosis 🔬. Here, Pauline Bornert explains how Oncodesign Services established preclinical tools and disease readouts, to support your drug development. Read the blog here 👉 https://buff.ly/4hpyBU0 #fibrosis #model #inflammation #research #CROservices
Learn how we collaborated with Bicycle Therapeutics to develop a PK/PD modelling framework to predict preclinical biomarker level and tumour growth inhibition in response to changes in dose and dosing schedule for BT7480. Check out our poster: https://lnkd.in/dyrDxrQ9
Psy Data Juggler | AI & Big Data Analysis | Data Scientist | Happy to follow/connect 😀 | Networking brings the world closer 💫 |
Accelerating Drug Discovery with ceSAR Approach 🧬 Innovative Approach: The ceSAR method combines transcriptional signature connectivity with molecular docking to enhance drug discovery and repurposing, reducing false positives and computational costs. #DrugDiscovery #Innovation 🔬 Mechanistic Insight: By integrating transcriptional data with chemical similarity and docking, ceSAR identifies potential drug candidates without needing target protein structures. #Pharmacogenomics #InSilicoResearch 🌍 Broad Implications: This method accelerates finding treatments for diseases by repurposing existing drugs, potentially revolutionising precision medicine. #PrecisionMedicine #Healthcare 💡 Research Applications: Demonstrates effective discovery of new inhibitors, such as BCL2A1 inhibitors for melanoma, showing ceSAR's utility in various therapeutic areas. #CancerResearch #Therapeutics Check it out here: https://lnkd.in/eJqHcwyV Also here: https://lnkd.in/e2f2DJ7h
